1Jochmus I, Schafen K, Kaath S, et al. Chimeric virus-like particles of the human papillomavirus type 16 as a prophylactic and therapeutic vaccine[J]. Arch Med Res, 1999,30(6):269-274. 被引量：1
2Ma TH. Environmental monitoring activities of the international programme on plant bioassays[J]. EMS Neusletter, 1999,25(2):6-8. 被引量：1
3Riethodorf L, Riethodorf L, Milde-Langosch K, et al. Differences in HPV 16 and HPV 18 E6/E7 oncogene expression between in situ and invasive adenocarcinoma of the cervix uteri [J].Virchow Arch, 2000,437(4) :491-500. 被引量：1
4Seavey SE, Holubar M, Saucedo LJ, et al. The E7 oncoprotein of human papillomavirus type 16 stablizes p53 through a mechanism independent of p19ARF[J]. J Virol, 1999,73 (9):7590-7598. 被引量：1
5Zhou J, Liu WJ, Peng SW, et al. Papillomavirus capsid protein expression level dependents on the match between codon usage and tRNA availability[J]. J Virol, 1999,73(6):4972-4982. 被引量：1
6Le-Buanec HD, Anna R, Lachgar A, et al. HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes [J]. Biomed Pharmacother, 1999,53(9):424～432. 被引量：1
